MX359947B - EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. - Google Patents
EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.Info
- Publication number
- MX359947B MX359947B MX2013010507A MX2013010507A MX359947B MX 359947 B MX359947 B MX 359947B MX 2013010507 A MX2013010507 A MX 2013010507A MX 2013010507 A MX2013010507 A MX 2013010507A MX 359947 B MX359947 B MX 359947B
- Authority
- MX
- Mexico
- Prior art keywords
- interferon
- patient
- flu
- severity
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452807P | 2011-03-15 | 2011-03-15 | |
| US201161476930P | 2011-04-19 | 2011-04-19 | |
| PCT/US2012/029201 WO2012125809A1 (en) | 2011-03-15 | 2012-03-15 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010507A MX2013010507A (es) | 2014-04-30 |
| MX359947B true MX359947B (es) | 2018-10-17 |
Family
ID=46045072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010507A MX359947B (es) | 2011-03-15 | 2012-03-15 | EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US9198955B2 (enExample) |
| EP (1) | EP2686002B1 (enExample) |
| JP (2) | JP6279905B2 (enExample) |
| KR (1) | KR102050339B1 (enExample) |
| CN (1) | CN103702680A (enExample) |
| AU (1) | AU2012229104B2 (enExample) |
| BR (1) | BR112013023609A8 (enExample) |
| CA (1) | CA2846786C (enExample) |
| CY (1) | CY1120176T1 (enExample) |
| DK (1) | DK2686002T3 (enExample) |
| EA (1) | EA028448B1 (enExample) |
| ES (1) | ES2666850T3 (enExample) |
| HR (1) | HRP20180621T1 (enExample) |
| HU (1) | HUE036931T2 (enExample) |
| IL (1) | IL228425A (enExample) |
| LT (1) | LT2686002T (enExample) |
| MX (1) | MX359947B (enExample) |
| PL (1) | PL2686002T3 (enExample) |
| PT (1) | PT2686002T (enExample) |
| RS (1) | RS57175B1 (enExample) |
| SG (1) | SG193446A1 (enExample) |
| SI (1) | SI2686002T1 (enExample) |
| SM (1) | SMT201800221T1 (enExample) |
| WO (1) | WO2012125809A1 (enExample) |
| ZA (1) | ZA201306933B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125809A1 (en) * | 2011-03-15 | 2012-09-20 | Biogen Idec Inc. | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
| HK1226092A1 (zh) * | 2014-01-09 | 2017-09-22 | Kyushu University, National University Corporation | 制备小胶质细胞的方法 |
| WO2018056584A1 (ko) | 2016-09-21 | 2018-03-29 | 삼성전자 주식회사 | 피부 상태 측정 방법 및 이를 위한 전자 장치 |
| CN116391233A (zh) * | 2020-09-30 | 2023-07-04 | 皇家飞利浦有限公司 | 用于执行剂量滴定的方法和系统 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
| DE3273787D1 (en) | 1981-02-04 | 1986-11-20 | Japan Found Cancer | Human interferon-beta gene |
| US4695543A (en) | 1982-03-23 | 1987-09-22 | Bristol-Myers Company | Alpha Interferon GX-1 |
| CA1302320C (en) | 1984-06-11 | 1992-06-02 | Hideo Niwa | Expression of human cromosomal interferon-_ in animal cells |
| US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
| FI90990C (fi) | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US5641656A (en) | 1993-10-22 | 1997-06-24 | University Of Connecticut | Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them |
| TR199901968T2 (xx) * | 1996-12-24 | 1999-12-21 | Biogen, Inc. | Sabit s�v� interferon form�lleri. |
| JP2001104482A (ja) * | 1999-10-07 | 2001-04-17 | Terumo Corp | ２室型プレフィルドシリンジ |
| ES2712469T3 (es) * | 2003-01-30 | 2019-05-13 | Becton Dickinson Co | Soporte con escudo de seguridad para un dispositivo de administración de fármaco |
| BRPI0510526A (pt) * | 2004-06-01 | 2007-10-30 | Ares Trading Sa | formulações lìquidas estabilizadas de interferon |
| US20060089593A1 (en) * | 2004-10-26 | 2006-04-27 | Sergio Landau | Needle-free injection device for individual users |
| EP1923085A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
| JP2010513309A (ja) * | 2006-12-18 | 2010-04-30 | アルタス ファーマシューティカルズ インコーポレイテッド | ヒト成長ホルモン製剤 |
| US9044378B2 (en) * | 2007-05-31 | 2015-06-02 | Safety Syringes, Inc. | Anti-needle stick safety device or system for use with drugs requiring reconstitution |
| JP5549048B2 (ja) * | 2007-08-16 | 2014-07-16 | 味の素株式会社 | 薬剤バイアルとプレフィルドシリンジの接続構造 |
| WO2010148337A1 (en) * | 2009-06-18 | 2010-12-23 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
| WO2012125809A1 (en) * | 2011-03-15 | 2012-09-20 | Biogen Idec Inc. | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
-
2012
- 2012-03-15 WO PCT/US2012/029201 patent/WO2012125809A1/en not_active Ceased
- 2012-03-15 PL PL12719487T patent/PL2686002T3/pl unknown
- 2012-03-15 ES ES12719487.6T patent/ES2666850T3/es active Active
- 2012-03-15 JP JP2013558168A patent/JP6279905B2/ja active Active
- 2012-03-15 EA EA201301024A patent/EA028448B1/ru unknown
- 2012-03-15 US US13/421,197 patent/US9198955B2/en active Active
- 2012-03-15 AU AU2012229104A patent/AU2012229104B2/en active Active
- 2012-03-15 EP EP12719487.6A patent/EP2686002B1/en active Active
- 2012-03-15 PT PT127194876T patent/PT2686002T/pt unknown
- 2012-03-15 SI SI201231281T patent/SI2686002T1/en unknown
- 2012-03-15 HU HUE12719487A patent/HUE036931T2/hu unknown
- 2012-03-15 RS RS20180455A patent/RS57175B1/sr unknown
- 2012-03-15 BR BR112013023609A patent/BR112013023609A8/pt not_active Application Discontinuation
- 2012-03-15 HR HRP20180621TT patent/HRP20180621T1/hr unknown
- 2012-03-15 SM SM20180221T patent/SMT201800221T1/it unknown
- 2012-03-15 CA CA2846786A patent/CA2846786C/en active Active
- 2012-03-15 SG SG2013069018A patent/SG193446A1/en unknown
- 2012-03-15 LT LTEP12719487.6T patent/LT2686002T/lt unknown
- 2012-03-15 CN CN201280019863.2A patent/CN103702680A/zh active Pending
- 2012-03-15 KR KR1020137027053A patent/KR102050339B1/ko active Active
- 2012-03-15 DK DK12719487.6T patent/DK2686002T3/en active
- 2012-03-15 MX MX2013010507A patent/MX359947B/es active IP Right Grant
-
2013
- 2013-09-12 ZA ZA2013/06933A patent/ZA201306933B/en unknown
- 2013-09-12 IL IL228425A patent/IL228425A/en active IP Right Grant
-
2015
- 2015-11-09 US US14/936,228 patent/US20160101157A1/en not_active Abandoned
-
2017
- 2017-09-05 US US15/695,587 patent/US10500254B2/en active Active
- 2017-09-05 JP JP2017170640A patent/JP6522069B2/ja active Active
-
2018
- 2018-04-23 CY CY20181100424T patent/CY1120176T1/el unknown
-
2019
- 2019-10-22 US US16/660,038 patent/US20200046804A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/827,282 patent/US20220280610A1/en not_active Abandoned
-
2025
- 2025-05-05 US US19/198,871 patent/US20250276042A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| BR112018067906A2 (pt) | métodos de tratamento de depressão usando antagonistas do receptor de orexina-2 | |
| BR112015027297A8 (pt) | administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| NI201400104A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| MX369259B (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| MX359947B (es) | EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| CU20130166A7 (es) | Composición farmacéutica en forma de una suspensión oral que comprende una fracción flavonoica y goma de xantano | |
| BR112015010651A2 (pt) | composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos | |
| BR112014015314A8 (pt) | composição farmacêutica não entérica compreendendo crofelemer | |
| EA201300096A1 (ru) | Лекарственный препарат, обладающий антибактериальным, противоязвенным и иммуномодулирующим действием | |
| CO2018013792A2 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo | |
| MX2015009681A (es) | Un medicamento combinado que comprende finilefrina y paracetamol. | |
| CL2013003268A1 (es) | Uso de una composición que comprende secnidazol y un antibiótico macrólido para preparar un medicamento útil en el tratamiento de infecciones dentales. | |
| DK2609926T3 (da) | Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat | |
| CL2013003671A1 (es) | Composicion y combinacion farmaceutica que comprende ketorolaco y meloxicam; proceso para preparar la composicion; uso en el tratamiento de la inflamacion y el dolor. | |
| ME02285B (me) | Farmaceutska jedinjenja koja sadrže beta galaktozidazu i alfa galaktozidazu i njihova upotreba za lečenje bolesti gastroezofagealnog refluksa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: PFIZER, INC. |
|
| GB | Transfer or rights |
Owner name: BIOGEN MA INC. |
|
| FG | Grant or registration |